REGENXBIO (NASDAQ:RGNX – Get Rating) and Vaxart (NASDAQ:VXRT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.
Insider & Institutional Ownership
80.2% of REGENXBIO shares are held by institutional investors. Comparatively, 38.7% of Vaxart shares are held by institutional investors. 12.7% of REGENXBIO shares are held by company insiders. Comparatively, 2.8% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
REGENXBIO has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| REGENXBIO | -248.68% | -45.51% | -29.55% |
| Vaxart | N/A | -79.47% | -60.62% |
Analyst Ratings
This is a summary of recent ratings and price targets for REGENXBIO and Vaxart, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| REGENXBIO | 0 | 2 | 4 | 0 | 2.67 |
| Vaxart | 0 | 1 | 2 | 0 | 2.67 |
REGENXBIO currently has a consensus target price of $40.86, suggesting a potential upside of 130.57%. Vaxart has a consensus target price of $4.75, suggesting a potential upside of 698.19%. Given Vaxart’s higher possible upside, analysts clearly believe Vaxart is more favorable than REGENXBIO.
Valuation and Earnings
This table compares REGENXBIO and Vaxart’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| REGENXBIO | $112.72 million | 6.83 | -$280.32 million | ($6.50) | -2.73 |
| Vaxart | $110,000.00 | 733.38 | -$107.76 million | ($0.84) | -0.71 |
Vaxart has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.
Summary
REGENXBIO beats Vaxart on 7 of the 13 factors compared between the two stocks.
About REGENXBIO
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
About Vaxart
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
